Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17048416 | 1.00 | CA2 (0.47) | CA2HCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL18356862 | 1.00 | CA2 (0.47) | CA2HCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL15701847 | 1.00 | CA2 (0.47) | CA2HCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL15701848 | 0.94 | CA2 (0.51) | CA2HCAR2ALDH1A1MGLLNPSR1 | |
| SCHEMBL23823922 | 0.89 | CA2 (0.43) | CA2HCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL15689786 | 0.88 | CA2 (0.47) | CA2HCAR2ALDH1A1MGLLNPSR1 | |
| SCHEMBL10032813 | 0.87 | CA2 (0.46) | CA2ALDH1A1MGLLNPSR1TMEM97 | |
| SCHEMBL20508221 | 0.87 | CA2 (0.48) | CA2ALDH1A1MGLLNPSR1TMEM97 | |
| SCHEMBL1357755 | 0.82 | CA2 (0.49) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL13063460 | 0.81 | CA2 (0.51) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295624-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2025-09-25 | — | — | US | disclosed |
| EP-3890721-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | Flagship Pioneering Innovations V, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20210299079-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2020118178-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3201168-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LTD (IN) | 2020-03-18 | — | — | EP | disclosed |
| US-9988340-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2018-06-05 | — | — | US | disclosed |
| US-9988340-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2018-06-05 | — | — | US | disclosed |
| US-9796659-B2 | Derivatives of polyhydroxy compounds | RATIOPHARM GMBH (DE) | 2017-10-24 | — | — | US | disclosed |
| US-9796659-B2 | Derivatives of polyhydroxy compounds | RATIOPHARM GMBH (DE) | 2017-10-24 | — | — | US | disclosed |
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| EP-3110789-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | ratiopharm GmbH (DE) | 2017-01-04 | — | — | EP | disclosed |
| WO-2016051420-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-07 | — | — | WO | disclosed |
| US-20160090350-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-03-31 | — | — | US | disclosed |
| US-20160090350-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-03-31 | — | — | US | disclosed |
| WO-2015128488-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2015-09-03 | — | — | WO | disclosed |
| US-9102649-B1 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9102649-B1 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299079-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | SLC16A1, SLC16A3, SLC16A8 | CA2 694/4885HCAR2 83/4885KEAP1 401/4885 |
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | TPMT, FH, FAH | CA2 2197/4885HCAR2 11/4885KEAP1 588/4885 |
| US-20160090350-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PMP22, SI, AQP4 | CA2 1611/4885HCAR2 431/4885KEAP1 1594/4885 |
| US-20250295624-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | SLC16A1, SLC16A3, SLC16A8 | CA2 694/4885HCAR2 83/4885KEAP1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.